Literature DB >> 28768995

Physiological Roles of Carnitine/Organic Cation Transporter OCTN1/SLC22A4 in Neural Cells.

Noritaka Nakamichi1, Yukio Kato1.   

Abstract

Dysfunction in neurotransmission mediated by neurotransmitters causes various neurological disorders. Therefore, receptors and reuptake transporters of neurotransmitters have been focused on as a therapeutic target in neurological disorders. These membrane proteins have high affinity for a specific neurotransmitter and are highly expressed on synaptic membranes. In contrast, xenobiotic transporters have relatively lower affinity for neurotransmitters but widely recognize various organic cations and/or anions and are also expressed in brain neurons. However, it has been largely unknown why such xenobiotic transporters are expressed in neurons that play a key role in signal transduction. We have therefore attempted to clarify the physiological roles of one such xenobiotic organic cation transporter (OCT) in neural cells with the aim of obtaining new insight into the treatment of neurological disorders. Carnitine/organic cation transporter OCTN1/SLC22A4 is functionally expressed in neurons and neural stem cells. In particular, OCTN1 is expressed at much higher levels compared with other OCTs in neural stem cells and positively regulates their differentiation into neurons. OCTN1 accepts the naturally occurring food-derived antioxidant ergothioneine (ERGO) as a good in vivo substrate. Because ERGO is highly distributed into the brain after oral ingestion, OCTN1 may contribute to the alleviation of oxidative stress and promotion of neuronal differentiation via the uptake of ERGO in the brain, perhaps abating symptoms of neurological disorders. In this review, we introduce current topics on the physiological roles of OCTs with a focus on OCTN1 in neural cells and discuss its possible application to the treatment of neurological disorders.

Entities:  

Keywords:  carnitine/organic cation transporter 1 (OCTN1); ergothioneine; neural stem cell; neurological disorder; neuron

Mesh:

Substances:

Year:  2017        PMID: 28768995     DOI: 10.1248/bpb.b17-00099

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  7 in total

Review 1.  Ergothioneine and central nervous system diseases.

Authors:  Noritaka Nakamichi; Sota Tsuzuku; Fumiya Shibagaki
Journal:  Neurochem Res       Date:  2022-07-05       Impact factor: 4.414

2.  The Alteration of L-Carnitine Transport and Pretreatment Effect under Glutamate Cytotoxicity on Motor Neuron-Like NSC-34 Lines.

Authors:  Asmita Gyawali; Seung Jae Hyeon; Hoon Ryu; Young-Sook Kang
Journal:  Pharmaceutics       Date:  2021-04-14       Impact factor: 6.321

Review 3.  Metformin Repurposing for Parkinson Disease Therapy: Opportunities and Challenges.

Authors:  Francesco Agostini; Anna Masato; Luigi Bubacco; Marco Bisaglia
Journal:  Int J Mol Sci       Date:  2021-12-30       Impact factor: 5.923

4.  A novel antioxidant ergothioneine PET radioligand for in vivo imaging applications.

Authors:  William J Behof; Clayton A Whitmore; Justin R Haynes; Adam J Rosenberg; Mohammed N Tantawy; Todd E Peterson; Fiona E Harrison; Robert B Beelman; Wellington Pham
Journal:  Sci Rep       Date:  2021-09-16       Impact factor: 4.379

5.  Effects of 1α,25-dihydroxyvitamin D3 on the pharmacokinetics and biodistribution of ergothioneine, an endogenous organic cation/carnitine transporter 1 substrate, in rats.

Authors:  Dang-Khoa Vo; Thi-Thao-Linh Nguyen; Han-Joo Maeng
Journal:  J Pharm Investig       Date:  2022-03-10

6.  Effect of Cholesterol on the Organic Cation Transporter OCTN1 (SLC22A4).

Authors:  Lorena Pochini; Gilda Pappacoda; Michele Galluccio; Francesco Pastore; Mariafrancesca Scalise; Cesare Indiveri
Journal:  Int J Mol Sci       Date:  2020-02-06       Impact factor: 5.923

Review 7.  OCTN1: A Widely Studied but Still Enigmatic Organic Cation Transporter Linked to Human Pathology and Drug Interactions.

Authors:  Lorena Pochini; Michele Galluccio; Mariafrancesca Scalise; Lara Console; Gilda Pappacoda; Cesare Indiveri
Journal:  Int J Mol Sci       Date:  2022-01-14       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.